StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Olopatadine

HCID 5281071
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
113806-05-6
Standard-SMILES
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21
InChIKey
JBIMVDZLSHOPLA-LSCVHKIXSA-N
Summenformel
C21H23NO3
Durchschnittliche Molmasse
337,4 g/mol
Monoisotopische Masse
337,1677936

Überblick

2-[11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid is a heterotricyclic compound.

Namen und Bezeichner

Bevorzugter Name
Olopatadine
IUPAC
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
Englischer Name
Olopatadine
Summenformel
C21H23NO3
Molmasse
337.41

Namen und Synonyme

Olopatadine113806-05-6Opatanol2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acidOlopatadinaAL-4943AD27V6190PM11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acidDTXSID3023390Olopatadinum2-((11Z)-11-(3-(dimethylamino)propylidene)-6H-benzo(c)(1)benzoxepin-2-yl)acetic acid2-((2Z)-2-(3-(dimethylamino)propylidene)-9-oxatricyclo(9.4.0.0^(3,8))pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl)acetic acid
Weitere Namen anzeigen
(Z)-2-(11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acidKW 4679propylidene)OlopatatadineOlopatadine(W.S)Olopatadine 13CD3Olopatadine HCl APIa-Hydroxy-OlopatadineOlopatadine Impurity E
2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acidRefChem:56799DTXCID603390R01AC08S01GX092-((2Z)-2-(3-(dimethylamino)propylidene)-9-oxatricyclo(9.4.0.03,8)pentadeca-1(15),3(8),4,6,11,13-hexaen-5-yl)acetic acidPatanolOlopatadine (INN)

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1,5
Polarare Oberfläche (TPSA)
49,8 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
5
Schwere Atome
25
Formalladung
0
Komplexität
488

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LogP3.4
Solubility3.13e-02 g/L
Human Drugs · 2 Einträge

Breast Feeding; Lactation; Anti-Allergic Agents; Antihistamines;

EMA approved medicines: Human medicine

Melting Point248 °C
Physical DescriptionSolid

Physikochemische Eigenschaften

Schmelzpunkt
188 · 188-189.5°
Siedepunkt
523 · 523.0±50.0 °C(Predicted)
Dichte
1 · 1+-.0.06 g/cm3(Predicted)
storage temp.
Amber Vial, Refrigerator
Löslichkeit
Chloroform (Slightly, Heated), DMSO (Slightly)
Aggregatzustand

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P273, P280, P301+P316, P318, P321, P330, P391, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxikologische Informationen

Exposure RoutesOphthalmic use of olopatadine usually does not produce measurable plasma concentrations.
Toxicity Summary · 1 Eintrag

Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.

Signs and Symptoms · 1 Eintrag

Its side effects may include headaches (7% of occurrence) burning and stinging (5%), dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pruritus, asthenia, cold syndrome, pharyngitis, rhinitis, sinusitis, and taste perversion. [Wikipedia]

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 4 Einträge

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 5 Einträge

S01GX09

S - Sensory organs

R - Respiratory system

QS - Sensory organs

QR - Respiratory system

Protein BindingAbout 55% of total olopatadine is bound to human serum proteins, with serum albumin being the primary protein of binding.
Pharmacodynamics · 1 Eintrag

Inflammatory reactions in response to various stimuli are mediated by endogenous mediators and other pro-inflammatory factors. Histamine receptor activation and mast cell degranulation are primary mechanisms that cause inflammatory reactions such as ocular itching, hyperemia, chemosis, eyelid swelling, and tearing of seasonal allergic conjunctivitis. Olopatadine is an anti-allergenic molecule and mast cell stabilizer that inhibits the _in vivo_ type 1 immediate hypersensitivity reaction. By blocking the effects of histamine, olopatadine works to reduce the symptoms of allergies and inflammation at various sites of administration, including the eyes and nose. It has shown to exert antihistaminic effects in isolated tissues, animal models, and humans. Olopatadine also demonstrated dose-dependent inhibition of immunologically-stimulated release of histamine from rat basophilic leukemia cells and human conjunctival mast cells _in vitro_. Olopatadine has a relatively rapid onset of action and prolonged duration, where it was shown to mediate anti-histaminic effects at 5 minutes to 24 hours post-administration. While olopatadine is a non-sedating antihistamine agent, there have been reports of somnolence in some patients taking nasal olopatadine during clinical trials. Temporary blurred vision or other visual disturbances were observed following ophthalmic administration. Olopatadine has negligible effects on alpha-adrenergic, dopamine, muscarinic type 1 and 2, and serotonin receptors. In clinical trials, there was no evidence of any effect of olopatadine on QT prolongation was observed following intranasal administration.

Mechanism of Action · 1 Eintrag

Histamine is a biogenic vasoactive amine that binds to its receptors, which are G-protein coupled receptors. Signaling through the histamine H1 receptor is thought to primarily promote the activation of inflammatory reactions, such as allergy, asthma, and autoimmune diseases. H1 receptor signaling activates the intracellular transcription factors, such as IP3, PLC, PKC, DAG, and intracellular calcium ions, which all work to activate further downstream cascades. Activated downstream cascades lead to the production of cytokines, the release of mast cell inflammatory mediators, synthesis of prostacyclins, activation of platelet factor, as well as the synthesis of nitric oxide, arachidonic acid, and thromboxane, which all contribute to inflammatory reactions. Olopatadine is an anti-allergic molecule that works via several mechanisms. As a mast cell stabilizer, it stabilizes rodent basophils and human conjunctival mast cells and inhibits the immunologically-stimulated release of histamine. Olopatadine acts as an antagonist at the histamine H1 receptors with high selectivity, which is explained by a unique receptor binding pocket that consists of the aspartate residue in the third transmembrane helix and other sites in the H1 receptor. Upon binding, olopatadine blocks the H1 receptor signaling pathway, inhibiting the release of inflammatory mediators, such as tryptase, prostaglandin D2, TNF-alpha, as well as pro-inflammatory cytokines. It also decreases chemotaxis and inhibits eosinophil activation. _In vitro_, olopatadine was shown to inhibit epithelial cell intercellular adhesion molecule-1 (ICAM-1), which promotes the recruitment of migrating pro-inflammatory mediators.

Zugehörige Reaktionen

2
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 422887
HRID 422887als Produkt
Reaktionsgleichung von HRID 2247135
HRID 2247135als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
113806-05-6
PubChem CID
5281071
DTXSID
DTXSID3023390
ChEMBL
CHEMBL1189432
ChEBI
CHEBI:94593
UNII
D27V6190PM
EC Number
601-282-3
Nikkaji
J3.342.980K、J485.528K
Solid
pka
4.29 · 4.29±0.10(Predicted)
Farbe
Pale Yellow to Pale Beige
Stabilität
Light Sensitive
InChI
InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
InChIKey
JBIMVDZLSHOPLA-LSCVHKIXSA-N
SMILES
O1CC2=CC=CC=C2/C(=C/CCN(C)C)/C2=CC(CC(O)=O)=CC=C12
CAS Datenbank
113806 · 113806-05-6(CAS DataBase Reference)

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Olopatadine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation · 2 Einträge

◉ Summary of Use during Lactation

◈ What is olopatadine?

Biological Half-LifeFollowing ocular administration, the elimination half-life of olopatadine was 3.4 ± 1.2 hours. In oral pharmacokinetics study, the elimination half-life was reported to be 8 to 12 hours.
Metabolism/Metabolites · 3 Einträge

Olopatadine undergoes hepatic metabolism in a non-extensive manner. Based on oral pharmacokinetic studies, there are at least 6 circulating metabolites in human plasma. Following topical ocular application of olopatadine, olopatadine N-oxide is formed by metabolism catalyzed by flavin-containing monooxygenase (FMO) 1 and 3 and was detected in the plasma after 4 hours post-dosing in less than 10% of the total plasma in half of the patients. Mono-desmethyl olopatadine, or N-desmethyl olopatadine, is formed by CYP3A4 and may be detected in minimal levels.

Olopatadine has known human metabolites that include N-monodemethylolopatadine.

The mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine. Route of Elimination: Elimination was predominantly through renal excretion. Half Life: 3 hours

FDA Pharmacological Classification · 6 Einträge

D27V6190PM

OLOPATADINE

Physiologic Effects [PE] - Decreased Histamine Release

Mechanisms of Action [MoA] - Histamine H1 Receptor Antagonists

Established Pharmacologic Class [EPC] - Histamine-1 Receptor Inhibitor

Established Pharmacologic Class [EPC] - Mast Cell Stabilizer

MeSH Pharmacological Classification · 3 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)

A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment.

Absorption, Distribution and Excretion · 4 Einträge

Ocular administration of olopatadine in healthy subjects resulted in the Cmax of 1.6 ± 0.9 ng/mL, which was reached after about 2.0 hours. The AUC was 9.7 ± 4.4 ngxh/mL. The average absolute bioavaiability of intranasal olopatadine is about 57%. Following intranasal administration in healthy subjects, the Cmax of 6.0 ± 8.99 ng/mL at steady-state was reached between 30 minutes to 1 hour after twice daily intranasal administration. The average AUC was 66.0 ± 26.8 ng·h/mL. In patients with seasonal allergic rhinitis, the Cmax of 23.3 ± 6.2 ng/mL at steady-state was reached between 15 minutes and 2 hours post-dosing and the average AUC was 78.0 ± 13.9 ng·h/mL.

Olopatadine is mainly eliminated through urinary excretion. Following oral administration, about 70% and 17% of the total dose was recovered in the urine and feces, respectively.

In an open-label study consisting of healthy Chinese subjects receiving oral administration of olopatadine, the mean apparent volume of distribution was 133.83 L.

In an open-label study consisting of healthy Chinese subjects receiving oral administration of olopatadine, the mean apparent oral clearance (CL/F) was 23.45 L/h.

Cellular LocationsCytoplasm
Metabolite PathwaysOlopatadine H1-Antihistamine Action

Verwendung und Herstellung

Uses · 2 Einträge

Use (kg) in USA (2002): 18

For the treatment of ocular itching associated with allergic conjunctivitis. Used as an antihistamine. [Wikipedia]

Anwendungen · 2 Einträge

BeschreibungOlopatadine belongs to a kind of antihistamine reagent. It is a relatively selective H1-receptor antagonist and can inhibit the histamine release process from the mast cell, subsequently leading to temporary relief on the negative symptoms associated with histamine. It is devoid of effects on alpha-adrenergic, dopamine and muscarinic type I and II receptors. Its 0.1% solution can be used for topical administration to the eyes. It is indicated for the treatment of itching associated with allergic conjunctivitis.

VerwendenOlopatadine is a dual acting histamine H1-receptor antagonist and mast cell stabilizer. Antiallergic; antihistaminic.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

ButyllithiumTrifluoressigsäure-anhydrid1,2-Dibromethanp-HydroxyphenylessigsureDiethylether-BortrifluoridNatriumpermanganatPhosphorylchloridPhthalid3-Chlorpropyl(dimethyl)aminMethyltriphenylphosphoniumbromidMethyl 2-(4-((2-bromobenzyl)oxy)phenyl)acetateBenzeneacetic acid, 4-[(2-bromophenyl)methoxy]-3-iodo-, methyl esterBenzeneacetic acid, 4-[(2-bromophenyl)methoxy]-3-(4-hydroxy-1-butyn-1-yl)-, methyl esterDibenz[b,e]oxepin-2-acetamide, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, (11Z)-, 4-methylbenzenesulfonate (1:1)UGDFSHGFPJSALM-OCKHKDLRSA-NIsoxepac(Z)-11-(3-dimethylaminopropylidene)-6,11-dihydro-dibenz-[b,e]oxepine-2-acetic acid hydrobromide